Literature DB >> 30866130

Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra-atrial thrombosis in severe haemophilia with an inhibitor.

Angela C Weyand1, Adam L Dorfman2, Jordan A Shavit1, Steven W Pipe1,3.   

Abstract

Entities:  

Year:  2019        PMID： 30866130     DOI： 10.1111/hae.13721

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  3 in total

1.  Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit.

Authors:  Donata Urbaniak-Kujda; Monika Maria Biernat; Tomasz Skalec; Jagoda Jacków-Nowicka; Jerzy Windyga; Tomasz Wróbel
Journal:  Haemophilia       Date:  2021-04-29       Impact factor: 4.263

2.  Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A.

Authors:  Kadhim Al-Banaa; Nicolas Gallastegui-Crestani; Annette von Drygalski
Journal:  Eur J Case Rep Intern Med       Date:  2021-11-11

3.  Management of COVID-19-associated coagulopathy in persons with haemophilia.

Authors:  Steven W Pipe; Radoslaw Kaczmarek; Alok Srivastava; Glenn F Pierce; Mike Makris; Cedric Hermans
Journal:  Haemophilia       Date:  2020-11-20       Impact factor: 4.263
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.